Naproxen adjunct to fluoxetine for moderate-to-severe obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial.
adverse drug reaction
combination drug therapy
neuroimmunomodulation
nonsteroidal anti‐inflammatory agents
randomized controlled trial
Journal
Psychiatry and clinical neurosciences
ISSN: 1440-1819
Titre abrégé: Psychiatry Clin Neurosci
Pays: Australia
ID NLM: 9513551
Informations de publication
Date de publication:
01 Oct 2024
01 Oct 2024
Historique:
revised:
15
08
2024
received:
27
06
2024
accepted:
04
09
2024
medline:
2
10
2024
pubmed:
2
10
2024
entrez:
2
10
2024
Statut:
aheadofprint
Résumé
Current treatments for obsessive-compulsive disorder (OCD) encounter resistance and limiting adverse events, necessitating novel therapeutic strategies. This study aimed to investigate the benefits of naproxen, a medication with effects on inflammation and neuronal function, on OCD. One hundred and four OCD outpatients with a Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score of >21 were equally assigned to receive fluoxetine plus either naproxen 250 mg or matched placebo q12hr. Patients were assessed using the Y-BOCS by recording the subscale scores at baseline and weeks 5 and 10 to evaluate efficacy. They were also assessed in terms of tolerability. Data from 96 patients were analyzed. The baseline characteristics were comparable between the groups. There were significant time-treatment interaction effects on the obsession subscale ( Naproxen, adjunct to fluoxetine, outperformed adjunctive placebo in treating obsession and total symptoms of OCD patients in a safe and tolerable manner. The study protocol was registered and published in the Iranian Registry of Clinical Trials (http://www.irct.ir; registration number IRCT20090117001556N139).
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Tehran University of Medical Sciences and Health Services
ID : 54718
Informations de copyright
© 2024 The Author(s). Psychiatry and Clinical Neurosciences © 2024 Japanese Society of Psychiatry and Neurology.
Références
Del Casale A, Sorice S, Padovano A et al. Psychopharmacological treatment of obsessive‐compulsive disorder (OCD). Curr. Neuropharmacol. 2019; 17: 710–736.
Kellner M. Drug treatment of obsessive‐compulsive disorder. Dialogues Clin. Neurosci. 2010; 12: 187–197.
Pallanti S, Quercioli L. Treatment‐refractory obsessive‐compulsive disorder: Methodological issues, operational definitions and therapeutic lines. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006; 30: 400–412.
Attwells S, Setiawan E, Wilson AA et al. Inflammation in the neurocircuitry of obsessive‐compulsive disorder. JAMA Psychiatry 2017; 74: 833–840.
Marazziti D, Mucci F, Fontenelle LF. Immune system and obsessive‐compulsive disorder. Psychoneuroendocrinology 2018; 93: 39–44.
Pauls DL, Abramovitch A, Rauch SL, Geller DA. Obsessive–compulsive disorder: An integrative genetic and neurobiological perspective. Nat. Rev. Neurosci. 2014; 15: 410–424.
Rodríguez N, Morer A, González‐Navarro EA et al. Inflammatory dysregulation of monocytes in pediatric patients with obsessive‐compulsive disorder. J. Neuroinflammation 2017; 14: 1–11.
Rao NP, Venkatasubramanian G, Ravi V, Kalmady S, Cherian A, Yc JR. Plasma cytokine abnormalities in drug‐naïve, comorbidity‐free obsessive–compulsive disorder. Psychiatry Res. 2015; 229: 949–952.
Pearlman DM, Vora HS, Marquis BG, Najjar S, Dudley LA. Anti‐basal ganglia antibodies in primary obsessive–compulsive disorder: Systematic review and meta‐analysis. Br. J. Psychiatry 2014; 205: 8–16.
van Roessel PJ, Grassi G, Aboujaoude EN, Menchón JM, Van Ameringen M, Rodríguez CI. Treatment‐resistant OCD: Pharmacotherapies in adults. Compr. Psychiatry 2023; 120: 152352.
Westwell‐Roper C, Best JR, Elbe D et al. Celecoxib versus placebo as an adjunct to treatment‐as‐usual in children and youth with obsessive‐compulsive disorder: Protocol for a single‐site randomised quadruple‐blind phase II study. BMJ Open 2022; 12: e054296.
Rao P, Knaus EE. Evolution of nonsteroidal anti‐inflammatory drugs (NSAIDs): Cyclooxygenase (COX) inhibition and beyond. J. Pharm. Pharm. Sci. 2008; 11: 81s–110s.
Fiebich B, Hüll M, Lieb K, Schumann G, Berger M, Bauer J. Potential link between interleukin‐6 and arachidonic acid metabolism in Alzheimer's disease. In: Alzheimer's Disease—From Basic Research to Clinical Applications. Springer, Vienna, 1998; 269–278.
Shalbafan M, Mohammadinejad P, Shariat SV et al. Celecoxib as an adjuvant to fluvoxamine in moderate to severe obsessive‐compulsive disorder: A double‐blind, placebo‐controlled, randomized trial. Pharmacopsychiatry 2015; 48: 136–140.
Housby JN, Cahill CM, Chu B et al. Non‐steroidal anti‐inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes. Cytokine 1999; 11: 347–358.
Oken RJ. Obsessive‐compulsive disorder: A neuronal membrane phospholipid hypothesis and concomitant therapeutic strategy. Med. Hypotheses 2001; 56: 413–415.
Sayyah M, Boostani H, Pakseresht S, Malayeri A. A preliminary randomized double‐blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive‐compulsive disorder. Psychiatry Res. 2011; 189: 403–406.
Shahini N, Talaei A, Shalbafan M, Faridhosseini F, Ziaee M. Effects of celecoxib adjunct to selective serotonin reuptake inhibitors on obsessive‐compulsive disorder. Basic Clin. Neurosci. 2021; 12: 489–498.
Grassi G, Cecchelli C, Vignozzi L, Pacini S. Investigational and experimental drugs to treat obsessive‐compulsive disorder. J. Exp. Pharmacol. 2020; 12: 695–706.
Spartz EJ, Freeman GM Jr, Brown K, Farhadian B, Thienemann M, Frankovich J. Course of neuropsychiatric symptoms after introduction and removal of nonsteroidal anti‐inflammatory drugs: A pediatric observational study. J. Child Adolesc. Psychopharmacol. 2017; 27: 652–659.
Brown KD, Farmer C, Freeman GM Jr et al. Effect of early and prophylactic nonsteroidal anti‐inflammatory drugs on flare duration in pediatric acute‐onset neuropsychiatric syndrome: An observational study of patients followed by an academic community‐based pediatric acute‐onset neuropsychiatric syndrome clinic. J. Child Adolesc. Psychopharmacol. 2017; 27: 619–628.
Sigra S, Hesselmark E, Bejerot S. Treatment of PANDAS and PANS: A systematic review. Neurosci. Biobehav. Rev. 2018; 86: 51–65.
Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. J. Pharmacol. Pharmacother. 2010; 1: 100–107.
Association WM. World medical association declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 2013; 310: 2191–2194.
First M, Williams J, Karg R. Association SRAP. Arlington, VA, American Psychiatric Association, 2015.
Goodman WK, Price LH, Rasmussen SA et al. The Yale‐Brown obsessive compulsive scale: I. Development, use, and reliability. Arch. Gen. Psychiatry 1989; 46: 1006–1011.
Medscape® L. Multi‐Drug Interaction Checker. Medscape, New York, 2017.
Wu MS, McGuire JF, Horng B, Storch EA. Further psychometric properties of the Yale–Brown obsessive compulsive scale—Second edition. Compr. Psychiatry 2016; 66: 96–103.
Askari N, Moin M, Sanati M et al. Granisetron adjunct to fluvoxamine for moderate to severe obsessive‐compulsive disorder: A randomized, double‐blind, placebo‐controlled trial. CNS Drugs 2012; 26: 883–892.
Farris SG, McLean CP, Van Meter PE, Simpson HB, Foa EB. Treatment response, symptom remission, and wellness in obsessive‐compulsive disorder. J. Clin. Psychiatry 2013; 74: 685–690.
Lakens D. Calculating and reporting effect sizes to facilitate cumulative science: A practical primer for t‐tests and ANOVAs. Front. Psychol. 2013; 4: 863.
Khandaker GM, Dantzer R, Jones PB. Immunopsychiatry: Important facts. Psychol. Med. 2017; 47: 2229–2237.
Mataix‐Cols D, Frans E, Pérez‐Vigil A et al. A total‐population multigenerational family clustering study of autoimmune diseases in obsessive‐compulsive disorder and Tourette's/chronic tic disorders. Mol. Psychiatry 2018; 23: 1652–1658.
Cosco TD, Pillinger T, Emam H et al. Immune aberrations in obsessive‐compulsive disorder: A systematic review and meta‐analysis. Mol. Neurobiol. 2019; 56: 4751–4759.
Alsheikh AM, Alsheikh MM. Obsessive‐compulsive disorder with rheumatological and inflammatory diseases: A systematic review. Cureus 2021; 13: e14791.
Brutzkus JC, Shahrokhi M, Varacallo M. Naproxen. StatPearls Publishing Copyright © 2024, StatPearls publishing LLC, Treasure Island (FL), 2024.
Kayser RR. Pharmacotherapy for treatment‐resistant obsessive‐compulsive disorder. J. Clin. Psychiatry 2020; 81: 19ac13182.
Wei H‐L, Xu C‐H, Wang J‐J et al. Disrupted functional connectivity of the amygdala predicts the efficacy of non‐steroidal anti‐inflammatory drugs in Migraineurs without Aura. Front. Mol. Neurosci. 2022; 15: 819507.
Cao L, Li H, Liu J et al. Disorganized functional architecture of amygdala subregional networks in obsessive‐compulsive disorder. Commun. Biol. 2022; 5: 1184.
Paul S, Beucke JC, Kaufmann C et al. Amygdala–prefrontal connectivity during appraisal of symptom‐related stimuli in obsessive–compulsive disorder. Psychol. Med. 2019; 49: 278–286.
Huey ED, Zahn R, Krueger F et al. A psychological and neuroanatomical model of obsessive‐compulsive disorder. J. Neuropsychiatry Clin. Neurosci. 2008; 20: 390–408.
Kaizaki A, Tien LT, Pang Y et al. Celecoxib reduces brain dopaminergic neuronaldysfunction, and improves sensorimotor behavioral performance in neonatal rats exposed to systemic lipopolysaccharide. J. Neuroinflammation 2013; 10: 45.
Sohel AJ, Shutter MC, Patel P, Molla M. Fluoxetine. StatPearls Publishing Copyright © 2024, StatPearls Publishing LLC, Treasure Island (FL), 2024.
Alam SM, Qasswal M, Ahsan MJ, Walters RW, Chandra S. Selective serotonin reuptake inhibitors increase risk of upper gastrointestinal bleeding when used with NSAIDs: A systemic review and meta‐analysis. Sci. Rep. 2022; 12: 14452.
Akhondzadeh S, Jafari S, Raisi F et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: A double blind and placebo controlled trial. Depress. Anxiety 2009; 26: 607–611.
Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S. Effect of celecoxib add‐on treatment on symptoms and serum IL‐6 concentrations in patients with major depressive disorder: Randomized double‐blind placebo‐controlled study. J. Affect. Disord. 2012; 141: 308–314.
Osani MC, Vaysbrot EE, Zhou M, McAlindon TE, Bannuru RR. Duration of symptom relief and early trajectory of adverse events for oral nonsteroidal antiinflammatory drugs in knee osteoarthritis: A systematic review and meta‐analysis. Arthritis Care Res. 2020; 72: 641–651.